6-[2-(2-chloro-4-methoxy-phenyl)-1-hydroxy-1-trifluoromethyl-propyl]-4-ethyl-4H-benzo[1,4]oxazin-3-one 、 、 三溴化硼 以
二氯甲烷 为溶剂,
以to give the title compound (1.57 g) as a light yellow solid的产率得到6-[2-(2-chloro-4-hydroxy-phenyl)-1-hydroxy-1-trifluoromethyl-propyl]-4-ethyl-4H-benzo[1,4]oxazin-3-one
参考文献:
名称:
2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS
[EN] 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS<br/>[FR] COMPOSES DE 1,1,1-TRIFLUORO-2-HYDROXYPROPYL A SUBSTITUTION 2,3-DIARYLE OU HETEROARYLE
申请人:HOFFMANN LA ROCHE
公开号:WO2010108903A1
公开(公告)日:2010-09-30
The present invention relates to compounds of formula (I), wherein R1a to R1e, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically 5 acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.
2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS
申请人:Hunziker Daniel
公开号:US20100249124A1
公开(公告)日:2010-09-30
The present invention relates to compounds of formula I
wherein R
1a
to R
1c
, R
2
, R
3
and R
5
are as defined in the description and claims and R
4
signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.
2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
申请人:Hoffmann-La Roche Inc.
公开号:US08268820B2
公开(公告)日:2012-09-18
The present invention relates to compounds of formula I
wherein R1a to R1c, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.